Hepatic fibrosis: Concept to treatment

Articles citing Hepatic fibrosis: Concept to treatment

Title / Author	Year
Mechanisms of hepatic stellate cell activation T Tsuchida, SL Friedman Nature reviews Gastroenterology & hepatology 14 (7), 397	2017
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis European Association for the Study of the Liver Journal of hepatology 69 (2), 406-460	2018
Immunology in the liver—from homeostasis to disease F Heymann, F Tacke Nature reviews Gastroenterology & hepatology 13 (2), 88	2016
Hepatic stellate cells as key target in liver fibrosis T Higashi, SL Friedman, Y Hoshida Advanced drug delivery reviews 121, 27-42	2017
Functional and genetic deconstruction of the cellular origin in liver cancer JU Marquardt, JB Andersen, SS Thorgeirsson Nature Reviews Cancer 15 (11), 653-667	2015
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets CY Zhang, WG Yuan, P He, JH Lei, CX Wang World Journal of Gastroenterology 22 (48), 10512	2016
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease G Arguello, E Balboa, M Arrese, S Zanlungo Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852 (9 …	2015
Pathophysiology of portal hypertension Y Iwakiri, RJ Groszmann The Liver: Biology and Pathobiology, 659-669	2020
Recent insights into the pathogenesis of nonalcoholic fatty liver disease JP Arab, M Arrese, M Trauner Annual Review of Pathology: Mechanisms of Disease 13, 321-350	2018
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis O Krenkel, T Puengel, O Govaere, AT Abdallah, JC Mossanen, ... Hepatology 67 (4), 1270-1283	2018
Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents V Calvaruso, G Cabibbo, I Cacciola, S Petta, S Madonia, A Bellia, F Tinè, ... Gastroenterology 155 (2), 411-421. e4	2018
Determinants of fibrosis progression and regression in NASH D Schuppan, R Surabattula, XY Wang Journal of hepatology 68 (2), 238-250	2018
Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells AK Horst, K Neumann, L Diehl, G Tiegs Cellular & molecular immunology 13 (3), 277-292	2016
Liver fibrosis: Direct antifibrotic agents and targeted therapies D Schuppan, M Ashfaq-Khan, AT Yang, YO Kim Matrix Biology 68, 435-451	2018
The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways K Zhang, X Han, Z Zhang, L Zheng, Z Hu, Q Yao, H Cui, G Shu, M Si, C Li, ... Nature communications 8 (1), 1-16	2017
Liver fibrosis: Common mechanisms and antifibrotic therapies D Schuppan Clinics and research in hepatology and gastroenterology 39, S51-S59	2015
Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease P Bedossa, K Patel Gastroenterology 150 (8), 1811-1822. e4	2016
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues M Parola, M Pinzani Molecular aspects of medicine 65, 37-55	2019
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction P Schwabl, E Hambruch, BA Seeland, H Hayden, M Wagner, L Garnys, ... Journal of hepatology 66 (4), 724-733	2017
The rationale for targeting TGF‐β in chronic liver diseases G Giannelli, W Mikulits, S Dooley, I Fabregat, A Moustakas, P ten Dijke, ... European Journal of Clinical Investigation 46 (4), 349-361	2016

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.